Forecasting Oncology Demand Trends with Boosting-Based Bayesian Conjugate Models
New hybrid model beats LSTM and XGBoost on trend forecasting for cancer care demand.
A team of Brazilian researchers—Ademir Batista dos Santos Neto, Tiago Alessandro Espinola Ferreira, and Paulo Renato Alves Firmino—has developed a novel Bayesian framework specifically for forecasting oncology demand trends. The model treats weekly appointments as a Poisson process with a Gamma prior, then enhances adaptability through a residual-based boosting mechanism built on a Gamma-Log-Normal conjugate structure. This hybrid approach allows the model to track both short-term fluctuations and long-term directional shifts while retaining the analytical tractability of conjugate Bayesian updating. The methodology was evaluated on real oncology service data from Cariri, Ceara, Brazil, providing a practical test bed for healthcare resource allocation.
The results are striking: the proposed model consistently outperformed established baselines including linear regression, ARIMA, naive forecasting, LSTM neural networks, and XGBoost. In terms of percentage of correct direction (a metric measuring trend detection accuracy), the Bayesian boosting model achieved gains of 38.25% over the second-best approach in some cases. This level of improvement could translate directly into better staffing, equipment, and budget planning for oncology departments. The paper (arXiv:2605.05270) is a strong signal that combining conjugate Bayesian methods with modern boosting techniques can yield practical, interpretable forecasting tools for healthcare systems facing increasing cancer care demands.
- Model combines Poisson-Gamma conjugate prior with residual boosting using Gamma-Log-Normal structure for adaptive trend tracking.
- Outperformed LSTM, XGBoost, ARIMA, linear regression, and naive forecasting by up to 38.25% in trend direction accuracy.
- Validated on real oncology appointment data from Cariri, Brazil, demonstrating practical applicability for resource planning.
Why It Matters
Better cancer demand forecasting enables hospitals to allocate staff and equipment precisely, improving patient outcomes and reducing costs.